Diagnos Laboratorium Utama PT Tbk
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want t… Read more
Diagnos Laboratorium Utama PT Tbk (DGNS) - Total Liabilities
Latest total liabilities as of June 2025: Rp110.07 Billion IDR
Based on the latest financial reports, Diagnos Laboratorium Utama PT Tbk (DGNS) has total liabilities worth Rp110.07 Billion IDR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Diagnos Laboratorium Utama PT Tbk - Total Liabilities Trend (2017–2024)
This chart illustrates how Diagnos Laboratorium Utama PT Tbk's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Diagnos Laboratorium Utama PT Tbk Competitors by Total Liabilities
The table below lists competitors of Diagnos Laboratorium Utama PT Tbk ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wilson Bayly Holmes Ovcon Ltd
JSE:WBO
|
South Africa | ZAC9.51 Billion |
|
Ouster, Inc. Warrants
NYSE:OUSTZ
|
USA | $106.33 Million |
|
Metal Bank Ltd
AU:MBK
|
Australia | AU$359.69K |
|
Xcel Brands Inc
NASDAQ:XELB
|
USA | $15.88 Million |
|
Galantas Gold Corporation
OTCQX:GALKF
|
USA | $23.50 Million |
|
Privasia Technology Bhd
KLSE:0123
|
Malaysia | RM189.12 Million |
|
Cheetah Net Supply Chain Service Inc. Class A Common Stock
NASDAQ:CTNT
|
USA | $2.66 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Diagnos Laboratorium Utama PT Tbk's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diagnos Laboratorium Utama PT Tbk's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diagnos Laboratorium Utama PT Tbk (2017–2024)
The table below shows the annual total liabilities of Diagnos Laboratorium Utama PT Tbk from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp103.89 Billion | +36.91% |
| 2023-12-31 | Rp75.88 Billion | +157.17% |
| 2022-12-31 | Rp29.51 Billion | -26.57% |
| 2021-12-31 | Rp40.18 Billion | +19.92% |
| 2020-12-31 | Rp33.51 Billion | +162.55% |
| 2019-12-31 | Rp12.76 Billion | +14.23% |
| 2018-12-31 | Rp11.17 Billion | +112.02% |
| 2017-12-31 | Rp5.27 Billion | -- |